ResearcherHarbin Medical UniversityNo recent work listed

Mei Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1312-382X; OpenAlex author ID A5101765232. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers

Papers 4

Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indi… Co-author DOI 10.3389/fonc.2019.01524 ↗
[Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma]. Last author DOI 10.3760/cma.j.issn.0529-5815.2019.03.009 ↗
miR-493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression. Co-author DOI 10.3892/ol.2017.7178 ↗
[Relationship and clinicopathological significance of Numb and epithelial-mesenchymal transition related proteins in human pancreatic cancer]. First author DOI 10.3760/cma.j.issn.0529-5815.2016.12.011 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lu Zhou · 1 shared paper, 2019 · strength 0.12
- Paper [Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma]. DOI 10.3760/cma.j.issn.0529-5815.2019.03.009 ↗
Duo Zhi · 1 shared paper, 2017 · strength 0.10
- Paper miR-493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression. DOI 10.3892/ol.2017.7178 ↗
Caichuan Yan · 1 shared paper, 2017 · strength 0.10
- Paper miR-493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression. DOI 10.3892/ol.2017.7178 ↗
Hui Li · 1 shared paper, 2019 · strength 0.09
- Paper Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-… DOI 10.3389/fonc.2019.01524 ↗
Huanjie Yang · 1 shared paper, 2019 · strength 0.09
- Paper Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-… DOI 10.3389/fonc.2019.01524 ↗
Xinyuan Li · 1 shared paper, 2019 · strength 0.09
- Paper Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-… DOI 10.3389/fonc.2019.01524 ↗
Dongyuan Wu · 1 shared paper, 2019 · strength 0.09
- Paper Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-… DOI 10.3389/fonc.2019.01524 ↗
Sheng Ww · 1 shared paper, 2016 · strength 0.07
- Paper [Relationship and clinicopathological significance of Numb and epithelial-mesenchymal transition related proteins in hu… DOI 10.3760/cma.j.issn.0529-5815.2016.12.011 ↗
Q Dong · 1 shared paper, 2016 · strength 0.07
- Paper [Relationship and clinicopathological significance of Numb and epithelial-mesenchymal transition related proteins in hu… DOI 10.3760/cma.j.issn.0529-5815.2016.12.011 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.